Hepatitis B reactivation and outcomes in persons treated with directly acting antiviral agents against hepatitis C virus: results from ERCHIVES
ConclusionsHBV‐r is relatively uncommon after DAA therapy and not higher than among those treated with a PEG/RBV regimen. The small numbers of persons treated with a DAA regimen who do develop HBV‐r have a shortened survival compared to those without HBV‐r.
Source: Alimentary Pharmacology and Therapeutics - Category: Drugs & Pharmacology Authors: A. A. Butt, P. Yan, O. S. Shaikh, A. ‐B. Abou‐Samra Tags: ORIGINAL ARTICLE Source Type: research